T he growth, repair, and regeneration of blood vessels are complex processes that involve coordinated regulation of endothelial cell proliferation, migration, and differentiation. 1 One of the most important vascular morphogens is vascular endothelial growth factor (VEGF). VEGF has been shown to play a major role in vasculogenesis and angiogenesis by gene deletion studies. 2, 3 Targeted disruption of the VEGF receptor Flk-1 (VEGFR-2) in mice resulted in failure of blood-island formation and endothelial differentiation. 4 Flk-1 is also the first endothelial receptor tyrosine kinase to be expressed in the hemangioblast. 5 We and others recently demonstrated that the hematopoietic progenitor cell CD34 ϩ can differentiate into endothelial cells, and that VEGF was one of the critical factors promoting this differentiation. 6, 7 Interactions between cells and their extracellular matrix (ECM) play an integral role in blood vessel development. The earliest ECM protein expressed in the embryo during vasculogenesis is fibronectin (FN). 8 Gene deletion studies have demonstrated that both FN and its major integrin receptor, ␣ 5 ␤ 1 , are critical for vasculogenesis and angiogenesis in the developing embryo. 9 -11 Collectively, these observations suggest important roles for FN and its integrin receptor, ␣ 5 ␤ 1 , in vasculogenesis and angiogenesis.
In this study, we show that novel VEGF binding domains of FN are required for promoting the specific association of the FN receptor integrin ␣ 5 ␤ 1 with the VEGF receptor, Flk-1. This association between VEGF and FN is required for the full effects of VEGF-induced endothelial cell migration and proliferation. This study demonstrates that FN can profoundly affect VEGF biological activity and consequently the behavior of endothelial cells through their coordinated effects on Flk-1 and ␣ 5 ␤ 1 .
Materials and Methods

Solid-Phase VEGF Binding Assay
ECM proteins and FN peptides were purchased from Sigma and Gibco and were purified further by gel filtration and ion exchange chromatography. Microtiter plates were coated with the appropriate ECM proteins (50 L; 10 g/mL) in 100 mmol/L bicarbonate buffer (pH 9) overnight at 4°C.
125
I-VEGF 165 (NEN) in binding buffer (PBS containing 2% BSA) was added to the microtiter plates and incubated for 30 minutes at room temperature. After washing, radioactivity was eluted with 100 mmol/L NaOH and determined using a gamma counter. To determine nonspecific binding, 100-fold excess of cold VEGF was added to the binding buffer and counts subtracted from the total binding.
Slot Blot Assay
ECM protein or FN peptides (2.5 g of each ) were immobilized on nitrocellulose membranes and incubated with 50 ng/mL VEGF 165 (R&D Systems) for 1 hour at 37°C in 20 mmol/L Tris, pH 7.5/0.15 mmol/L NaCl/0.1% BSA. The membranes were incubated with mouse anti-human VEGF antibody (R&D Systems), followed by goat anti-mouse HRP-conjugated in binding buffer for 30 minutes each. All blots were visualized by chemiluminescence (Pierce).
Surface Plasmon Resonance Analysis (SPR)
SPR analysis was performed on the BIAcore X (Biacore). FN fragments were coupled to CM5 dextran chips by amine coupling chemistry according to the manufacturer's protocols. 
Immunoprecipitation of VEGF/FN Complex From Platelet Supernatants
Washed platelets were prepared as previously described. 12 Platelets were resuspended in the presence of 1.5 mmol/L calcium and at a count of 30ϫ10 8 /mL. One milliliter of platelets was stimulated with either saline (resting) or thrombin (1 U/mL) for 10 minutes. Supernatants were immunoprecipitated with an antibody to FN (Chemicon). After SDS-PAGE and electrotransfer to PVDF membranes, VEGF was detected with a polyclonal antibody (Santa Cruz) by immunoblotting and chemiluminesescence detection.
Immunoprecipitation
Human microvessel endothelial cells (HMVECs) in serum-free MCDB-131 medium (BioWhittaker) supplemented with 0.1% BSA were plated on polylysine (1 mg/mL), FN (10 g), vitronectin (VN; 10 g/mL), or FN peptide (50 g/mL) coated plates containing VEGF (50 ng/mL) for 1 hour. Cells were lysed with lysis buffer (20 mmol/L HEPES, pH 7.5, 0.5% Brij 35, 0.5% NP-40, 100 mmol/L NaCl, 5% glycerol, 0.1% BSA and protease inhibitors) and immunoprecipitated with antibodies to
. After SDS-PAGE and protein transfer, membranes were immunoblotted with antibodies to Flk-1 (Santa Cruz). Bands were detected by chemiluminescence.
Migration Assay
Migration studies were carried out using 6.5-mm Transwells (Costar). VEGF (50 ng/mL) and ECM (10 g/mL) or FN fragment (50 g/mL) mixtures in MCDB 131 medium containing 0.5% bovine serum albumin were added to the bottom chambers of the Transwell and incubated at 37°C for 30 minutes. HMVECs (5ϫ10 4 ) were then placed in the upper chamber in the same medium and the Transwells were incubated for a further 6 hours at 37°C. Transwells were processed as described previously. 13 For studies on the effect of antibodies to integrins, HMVECs were preincubated for 30 minutes with the indicated antibodies before addition to the upper chamber of Transwells. The lower chamber contained VEGF (50 ng/mL), FN, and VN (10 g/mL).
MAPK In Vitro Kinase Assay
HMVECs were lysed, and MAPK was immunoprecipitated using a pan MAPK antibody (Pharmigen), washed in 50 mmol/L Tris-HCL, pH 7.4, containing 120 mmol/L NaCl, 0.1% Triton-X-100, and 10% glycerol. After washing in kinase buffer (50 mmol/L Tris-HCL, pH 7.4, 0.5 mmol/L DTT, 10 mmol/L MgCl 2 , 10 mmol/L MnCl 2 , 120 mmol/L NaCl, and 10% glycerol), the immunoprecipitates were incubated for 15 minutes at 30°C in 30 L of kinase buffer containing 2.5 g myelin basic protein, 20 mol/L ATP, and 10 Ci/nmol [␥-
32 P]ATP (3000 Ci/mmol). Reactions were stopped with 4ϫ SDS-PAGE sample buffer, resolved by 10% SDS-PAGE. Radioactivity incorporated into the myelin basic protein bands were determined by Cerenkov counting.
Results
Intact FN Promotes VEGF-Induced Endothelial Cell Migration
Endothelial cell migration was slightly enhanced by either VEGF or FN alone. But the combination of VEGF/FN increased migration by 2.5-fold over VEGF alone or VEGF/vitronectin (VN) and VEGF/collagen mixtures ( Figure 1 ). Because FN has proteolytic fragments that are chemotatic for endothelial cells, 14 we tested the effect of FN fragments combined with VEGF on VEGF-induced endothelial cell migration (see map of fragments, Figure 5B ). When endothelial cells were exposed to VEGF and only the FN 120-kDa cell-binding domain peptide, no enhancement of endothelial cell migration was observed ( Figure 1 ). Adding both the 70-kDa N-terminal and the 40-kDa C-terminal FN peptides to the VEGF/120-kDa FN peptide mixture failed to restore endothelial migration to levels observed with the VEGF/intact FN combination ( Figure 1 ). To determine whether intact FN was enhancing VEGF-induced migration by protecting VEGF from proteolysis, we compared the rates of VEGF degradation by plasmin in the absence or presence of FN and VN. VEGF alone was completely degraded within 15 minutes. Both FN and VN did significantly protect VEGF from degradation, but VN was as effective as FN (Ϸ50% degraded after 4 hours in the presence of FN or VN; data not shown).
␣ 5 ␤ 1 Integrin Mediates VEGF/FN-Induced Migration
Although ␣ 5 ␤ 1 is the key receptor for FN, other integrin receptors such as ␣ v ␤ 3 , the major receptor for VN, can also bind FN. To determine the integrin responsible for the enhanced migration, endothelial cells were exposed to a mixture of VEGF/FN/VN, and migration measured across a combined FN/VN substrate. By using specific integrin-blocking antibodies, the integrin responsible for migration could be identified. In the presence of antibodies to ␣ 5 ␤ 1 , VEGF-induced cell migration across the mixed FN/VN substrate was suppressed, whereas antibodies to ␣ v ␤ 1 , ␣ v ␤ 3 , or ␣ v ␤ 5 had no effect (Figure 2 ). This inhibition of migration by antibodies to ␣ 5 ␤ 1 was not due to suppression of cell adhesion because endothelial cells were still able to attach to the FN/VN through ␣ v ␤ 3 (data not shown). In addition, soluble flt-1, a high-affinity receptor for VEGF, blocked migration by over 70%.
VEGF Receptor Flk-1 Associates With Integrin
We next studied how the VEGF/FN mixtures might influence the association of their respective receptors. Incubating endothelial cells on VEGF/FN-coated plates promoted the association of Flk-1 receptor (VEGFR-2) with ␣ 5 ␤ 1 as demonstrated by immunoprecipitation and Western blotting (Figure 3A) . Flt-1 receptor (VEGFR-1) did not coprecipitate with Figure 4A ). Figure 4B shows that U0126, a specific MAP kinase inhibitor, blocked endothelial cell migration by 90%, whereas wortmannin, a PI3-kinase inhibitor, suppressed migration by 20%.
FN Contains Two VEGF Binding Sites
Using the solid-phase assay, the binding of VEGF to a variety of ECM proteins was tested. 125 I-VEGF 165 bound mainly to FN ( Figure 5A ). Binding of VEGF was also observed with fibrin and fibrinogen (recently reported 17 ). VEGF did not bind to vitronectin or collagen I, III, or IV. To locate the VEGF binding site on the FN molecule, slot blot assays were performed using purified proteolytically cleaved FN fragments immobilized onto nitrocellulose membranes. VEGF bound strongly to the 70-kDa N-terminal fragment (70-kDa FN peptide) and the 40-kDa C-terminal fragment (40 kDa FN peptide; Figure 5B ). Binding was not observed with the 120-kDa internal cell binding domain fragment (120-kDa peptide; data not shown). Equivalent binding to FN was also observed with VEGF 121 (data not shown).
To confirm the observations of the slot blot assays, the equilibrium binding of VEGF to the 70-kDa FN peptide was quantified over a range of concentrations using surface plasma resonance analysis (SPR). As shown in Figure 6 , VEGF bound to the 70-kDa FN peptide immobilized on the sensor chip in a specific and saturable manner. The estimated Kd was 2 mol/L. VEGF binding to the 40-kDa FN peptide could not be measured directly by SPR because immobilization of the 40-kDa FN peptide appeared to mask the VEGF binding site. Accordingly, the Kd for VEGF binding to the 
VEGF/FN Complex Formation In Vivo
To determine whether VEGF/FN complexes were spontaneously formed after platelet activation, we immunoprecipitated the supernatants from resting and thrombin-activated platelets with an antibody to FN. Precipitation of FN from supernatant of thrombin-activated platelets caused significant coprecipitation of VEGF compared with resting platelets or to a negative control antibody ( Figure 7A ). To determine whether the VEGF/FN complex was biologically active, supernatants from thrombin-activated platelets were filtered through Amicon filters (10 5 -kDa cut-off) to obtain VEGF/FN complexes. The presence of these complexes was confirmed by immunoprecipitation. Filtered supernatants from thrombinstimulated platelets promoted endothelial cell migration (Figure 7B) . Addition of soluble Flt-1, a high-affinity receptor for VEGF, inhibited endothelial cell migration by 25%. Blocking antibody to ␣ 5 ␤ 1 inhibited migration by 45%. The combination of both soluble Flt-1 and anti-␣ 5 ␤ 1 inhibited migration by more than 60%.
Discussion
In this study, we demonstrate that VEGF binding to FN serves to amplify the biological effects of VEGF. Specific VEGF binding domains within FN were required to promote sustained MAP kinase activation and endothelial cell migration. The observation that both VEGF-165 and VEGF-121 can bind FN suggests that their FN binding ability is contained within exons 1 to 5 or 8. The VEGF binding domains on FN were mapped to the 70-kDa N-terminal and 40-kDa C-terminal ends of the FN molecule. Although the 40-and 70-kDa FN fragments bound VEGF, these fragments on their own were not sufficient to exert the full biological effect of enhanced migration seen with the intact FN molecule. One possible explanation is that the 70-and 40-kDa fragments do not fully support ␣ 5 ␤ 1 adhesion and that an intact FN molecule containing both the cell binding and VEGF binding domains is required to facilitate the association of ␣ 5 ␤ 1 with Flk-1 to promote enhanced cell migration. These findings identify the VEGF binding domains on intact FN as important cofactors for initiating a signaling pathway mediated by the ␣ 5 ␤ 1 /Flk-1 complex (Figure 8) .
The integration of signals from integrins and receptor tyrosine kinases is essential in mediating cellular events such as cell proliferation, migration, and differentiation. 18 -22 Several recent studies have demonstrated that integrins and growth factor receptors can interact to form functional complexes although the mechanism(s) by which they associate to integrate their signals is unclear. For example, recent reports have demonstrated association of the ␤ 1 integrin with VEGFR-3 (Flt4) that is required for cell migration 23 and that Figure 7 . VEGF/FN complex secreted by activated platelets is biologically active. A, One milliliter of platelets (30ϫ10 8 ) was stimulated with either saline (resting) or thrombin (1 U/mL) for 10 minutes. Resting supernatant or thrombin-activated supernatant was immunoprecipitated with an antibody to FN or control IgG 1 followed by immunoblotting with a VEGF polyclonal antibody. B, Resting and thrombin supernatants were spun through Amicon 100. Sample concentration was kept constant by adding resuspension buffer. For migration assay, the supernatants (resting and thrombin-stimulated) were used at 0.3 mg/mL and carried out as described in the Materials and Methods section. Soluble Flt-1 receptor was added at a concentration of 1 g/mL. Antibody to ␣ 5 ␤ 1 was added at 10 g/mL. 
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platelet-derived growth factor (PDGF) in the presence of vitronectin induces the association of the PDGF-␤ receptor with the ␣ v ␤ 3 integrin to enhance PDGF-BB induced proliferation and migration of fibroblasts. 16,24 -26 The ␣ 6 ␤ 4 and ␣ 6 ␤ 1 integrins have been shown to associate with ErB-2 in human carcinoma cell lines after stimulation with epidermal growth factor or insulin. 27 In addition, binding of tenascin-C to ␣ v ␤ 3 was shown to promote epidermal growth factor (EGF) receptor recruitment to focal adhesions, which resulted in increased smooth muscle cell proliferation, and that sustained activation of MAP kinase by EGF required ␣ v ␤ 3 aggregation. 28, 29 Recently, it was demonstrated that PDGF-␤ and Flk-1 associated with the ␤ 3 integrin through its extracellular domain. However, it is still unclear how growth factors complexed to ECM proteins mediate the association of growth factor receptors and integrins. Indeed, several recent reports have demonstrated binding of soluble growth factors to ECM proteins. Fibrinogen was shown to bind both bFGF and VEGF and promote the proliferative effects of bFGF, 17, 30 whereas tenascin-X was shown to bind VEGF-B. 31 Vitronectin was also shown to bind VEGF. 32 The binding of VEGF to heparan sulfate proteoglycan in ECM protects VEGF from proteolytic degradation. Bound VEGF can be released in a soluble and bioactive form by heparin and plasmin. 33 Although a strong association between Flk-1 and ␣ 5 ␤ 1 was observed when endothelial cells were plated on FN/VEGFcoated plates, we also, consistent with two other reports, observed a weak physical association between Flk-1 and ␣ v ␤ 3 when VN was the substrate. 15, 16 When compared with the Flk-1/␣ 5 ␤ 1 association, Flk-1/␣ v ␤ 3 association did not translate into prolonged MAP kinase activity or endothelial cell migration. One plausible explanation for VEGF/FN promotion of MAP kinase activation and endothelial cell migration versus VEGF/VN is that the VEGF binding domains on FN may help bridge the Flk-1 and ␣ 5 ␤ 1 receptors for signal amplification. This is supported by the observation that the synergistic effects of VEGF/FN on endothelial cell migration, VEGF/Flk-1 association, and MAP kinase activation requires intact FN molecules. In support of our observations, it was shown recently that breast cancer cells had a higher rate of proliferation and migration in response to VEGF when cultured on a FN substrate. 34 The enhanced biological effects of the VEGF/FN complexes observed in this study were not due to the protective effects of FN on VEGF because both FN and VN equally protected VEGF degradation by plasmin. Further work will be needed to elucidate the structurefunction relationship important for the coordinate actions of VEGF/FN.
Using specific inhibitors to MAP kinase and PI3-kinase, we demonstrate that MAP kinase activation is important for VEGF/FN-induced endothelial cell migration. MAP kinase inhibition resulted in almost total suppression of endothelial cell migration, whereas PI3-kinase inhibition only resulted in Ϸ20% inhibition. This observation, in contrast to a recent study, 35 may be due to the presentation to the cell of VEGF as a complex with FN. Consistent with our studies, fibroblasts obtained from MEK-1-deficient mice failed to migrate on FN. Re-expression of functional MEK-1 in the mutant fibroblasts restored their ability to migrate on FN, 36 suggesting that MAP kinase may play an important role in ␣ 5 ␤ 1 -mediated migration. Indeed, several other studies have provided evidence that sustained activation of MAP kinase may play a role in cell migration 37 by phosphorylation and activation of myosin light chain kinase as well as regulating focal adhesion assembly. 38, 39 It is known that platelets are a major source of VEGF, and activated platelets release VEGF. 40 This present study shows that platelets release VEGF complexed to FN. This is a significant finding with regard to the process of neovascularization in wound healing and tumor angiogenesis. This suggests that growth factors in general are released from activated platelets complexed to ECM. The formation of a complex may serve to protect the growth factor from degradation and also to integrate the signals generated by integrins and receptor tyrosine kinases.
In summary, we have identified two novel VEGF binding domains on the 70-kDa N-terminal and 40-kDa C-terminal FN molecule, which we propose are necessary for promoting the physical association of ␣ 5 ␤ 1 and Flk-1. This association of integrin and receptor tyrosine kinase enhances the amplification of signals required for sustained activation of MAP kinase and subsequent endothelial cell migration. These present data provide further insights into mechanisms by which growth factors and ECM cooperate to influence cellular behavior.
